Telisotuzumab-EMRELIS applicable cancer types and clinical treatment options for different patients

Telisotuzumab-EMRELIS is a monoclonal antibody targeting the c-Met receptor and is mainly used to treat solid tumors expressing c-Met. c-MetThe receptor is highly expressed in a variety of tumors, including non-small cell lung cancer (NSCLC), gastric cancer, breast cancer, etc. Abnormal activation of the c-Met signaling pathway is closely related to tumor cell proliferation, metastasis and drug resistance. By targeting c-Met, terituzumab can inhibit tumor growth and induce tumor cell apoptosis, providing new targeted treatment options for patients with these tumors.

In terms of clinical treatment plan design, terituzumab can be used as second-line or later-line treatment for patients with non-small cell lung cancer, especially those who have relapsed or progressed after previously receiving first-line chemotherapy or targeted drug treatment. The conventional regimen is intravenous infusion, and the dose per cycle is adjusted based on body weight and individual tolerance, usually once every three weeks. Patients need to closely monitor adverse reactions during the first dose and early course of treatment to ensure treatment safety, and at the same time evaluate efficacy indicators, such as tumor volume changes and survival time.

The clinical application of territuzumab also varies for different patient groups. Elderly patients or patients with mild to moderate hepatic and renal insufficiency can appropriately adjust the dose or extend the dosing interval to reduce toxic and side effects while ensuring safety. For patients with good physical condition and high tumor burden, they can be administered continuously at standard doses in order to obtain the best therapeutic effect. The length of treatment can be dynamically adjusted based on the patient's response and tolerance, and is generally continued until disease progression or intolerable side effects occur.

In addition, the application of terituzumab in combination therapy is also under clinical exploration. Some studies have tried to combine it with chemotherapy, immune checkpoint inhibitors or other targeted drugs to improve efficacy and delay drug resistance. When using combined drugs, special attention should be paid to drug interactions and the cumulative risk of adverse reactions, and the dosage and treatment course should be adjusted through individualized plans to ensure that patients obtain the maximum therapeutic effect while controlling toxic and side effects within an acceptable range.

Keyword tags: Terituzumab, EMRELIS, indications, non-small cell lung cancer, c-Met, ADC drugs, treatment options, combination therapy.

Reference:https://en.wikipedia.org/wiki/Telisotuzumab_vedotin